News
OphthalmologyTimes
Jun 18, 2025
Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy
Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs Standard Control Organisation (CDSCO), India's national regulatory body for cosmetics, pharmaceuticals, and medical devices, for permission to start phase 2 of the study.
BioPharmaAPAC
May 8, 2025
India to Gain Faster, Affordable Access to CAR T Therapy as NKure Therapeutics Partners with CRISPR Therapeutics
Strategic collaboration to co-develop CTX112™ aims to address India’s growing burden of B-cell lymphomas with an off-the-shelf, CRISPR-engineered cell therapy offering scalable production and reduced treatment delays.
THE KEN
Apr 21, 2025
How a 14-member biotech spent just $10M on a product global pharma wants to lap up
One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price.
2022 All rights reserved
